Stroke prevention in atrial fibrillation: Current anticoagulation management and future directions

Cleveland Clinic Journal of Medicine

Volumn 72, Issue SUPPL.1, 2004, Pages

  Fitzgerald, Benjamin T ^a   Cohn, Steven L ^b   Klein, Allan L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; WARFARIN;

CEREBROVASCULAR ACCIDENT; HEART ATRIUM FIBRILLATION; HUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; WARFARIN;

EID: 84884549179     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.Suppl_1.S24     Document Type: Article

References (48)

1. Crystal E, Connolly SJ. Atrial fibrillation: guiding lessons from epidemiology. Cardiol Clin 2004; 22:1-8.
2. Easton JD, Sherman DG. Management of cerebral embolism of cardiac origin. Stroke 1980; 11:433-442.
3. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 1990; 322:863-868.
4. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406-1412.
5. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1255-1262.
6. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343:687-691.
7. Cowburn P, Cleland JGF. Clinical trial update: SPAF-III results. Eur Heart J 1996; 17; 1129.
8. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131:927-934.
9. Dunn M, Alexander J, de Silva R, Hildner F. Antithrombotic therapy in atrial fibrillation. Chest 1986; 89(Suppl 2):68S-74S.
10. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 1994; 25:40-43.
11. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for develop ment of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110:1042-1046.
12. Lip GY, Lip PL, Zarifis J, et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94:425-431.
13. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Hemostatic and hemodynamic abnormalities associated with left atrial thrombus in non-rheumatic atrial fibrillation. Heart 1997; 77:407-411.
14. Goldman ME, Pearce LA, Hart RG, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999; 12:1080-1087.
15. Ren JF, Marchlinski FE, Callans DJ. Left atrial thrombus associated with ablation for atrial fibrillation: identification with intracardiac echocardiography. J Am Coll Cardiol 2004; 43:1861-1867.
16. Hart RG, Pearce LA, McBride R, et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999; 30:1223-1229.
17. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449-1457.
18. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864-2870.
19. Snow V, Weiss KB, LeFevre M, et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003; 139:1009-1017.
20. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003; 290:1049-1056.
21. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1:175-179.
22. Vermeer F, Langenberg M, Hellemons BS, et al. Primary prevention of arterial thromboembolism in nonrheumatical atrial fibrillation (PATAF) [abstract]. J Am Coll Cardiol 1998; 31(Suppl A):344A.
23. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a metaanalysis. Ann Intern Med 1999; 131:492-501.
24. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences. Eur Heart J 2001; 22:1852-1923.
25. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106:388-391.
26. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl 3):429S-456S.
27. McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139:1018-1033.
28. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998; 158:1513-1521.
29. Kamath S, Blann AD, Chin BS, Lip GY. A prospective randomized trial of aspirin-clopidogrel combination therapy and doseadjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol 2002; 40:484-490.
30. Olsson SB; on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362:1691-1698.
31. Halperin JL. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. J Am Coll Cardiol 2005; 45:1-9.
32. SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 2005; 293:690-698.
33. He R. Integrated executive summary of FDA review for NDA 21-686: Exanta (ximelagatran). Available at: www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_03_FDA-Backgrounder-Execsummaryredacted.pdf. Accessed January 19, 2005.
34. Desai M. NDA 21-686: ximelagatran (H376/95). Indication: prevention of stroke and thromboembolic complications associated with atrial fibrillation. Available at: www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_06_FDA-Backgrounder-C-R-MOR.pdf. Accessed January 19, 2005.
35. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
36. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of ratecontrol versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41:1690-1696.
37. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834-1840.
38. Opolski G, Torbicki A, Kosior D, et al. Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study. Kardiol Pol 2003; 59:1-16.
39. Hohnloser SH, Kuck K-H, Lilienthal J, for the PIAF Investigators. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356:1789-1794.
40. Garcia-Fernandez MA, Perez-David E, Quiles J, et al. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. J Am Coll Cardiol 2003; 42:1253-1258.
41. Hanna IR, Kolm P, Martin R, Reisman M, Gray W, Block PC. Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): six-month echocardiographic follow-up. J Am Coll Cardiol 2004; 43:1868-1872.
42. Navia JL, Gillinov AM, McCarthy PM. Curative surgery for atrial fibrillation. Current status and minimally invasive approaches. Minerva Cardioangiol 2004; 52:155-168.
43. Cox JL, Ad N, Palazzo T. Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg 1999; 118:833-840.
44. Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized longterm study. J Am Coll Cardiol 2003; 42:185-197.
45. Kok LC, Ellenbogen KA. Device therapy for atrial fibrillation. Cardiol Clin 2004; 22:71-86.
46. Hsu LF, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004; 351:2373-2383.
47. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344:1411-1420.
48. Asher CR, Klein AL. Transesophageal echocardiography in patients with atrial fibrillation. Pacing Clin Electrophysiol 2003; 26(7 Pt 2): 1597-1603.